Bristol, Santaris to develop RNA drugs in deal with $100M potential

04/17/2013 | Genetic Engineering & Biotechnology News

Bristol-Myers Squibb and Santaris Pharma, which specializes in developing drugs against mRNA and microRNA targets, agreed to collaborate in the discovery and development of drugs using the latter's locked nucleic acid drug technology. Santaris will get research and discovery funding, as well as a $10 million upfront payment from Bristol. The deal also entitles Santaris to as much as $90 million in milestone fees per product plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX